A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Lead Sponsor

AbbVie (prior sponsor, Abbott)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Subject is \>= 18 years of age
•Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
•Subject is judged to be in generally good health as determined by the principal investigator

•Subject has previous exposure to systemic anti-IL 12 therapy
•Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
•Subject is taking or requires oral or injectible corticosteroids
•Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis or new onset guttate psoriasis
•Subject considered by the investigator, for any reason, to be an unsuitable candidate
•Female subject who is pregnant or breast-feeding or considering becoming pregnant

Related studies

NCT07474792 · Plaque Psoriasis

NCT06979453 · Plaque Psoriasis

NCT07116967 · Plaque Psoriasis

NCT07250802 · Plaque Psoriasis

NCT07449702 · Plaque Psoriasis